Cigna (CI) Stock Forecast & Price Target

Cigna Group is supported by a durable earnings mix that combines a scaled PBM and specialty pharmacy franchise with a steadier employer-focused health insurance business, allowing it to lean less on Medicare-heavy peers and more on commercial, self-funded membership. Management’s CY30 adjusted EPS floor of at least $45, along with a 10.0%-14.0% long-term adjusted EPS CAGR and about $50 billion of five-year cash flow guidance, signals meaningful compounding backed by capital deployment and operating leverage. The thesis is strengthened by Evernorth’s specialty growth, Cigna Healthcare’s 6.0%-9.0% earnings outlook, and visibility into roughly 69.9% of healthcare earnings growth through CY30 before efficiencies.

Cigna Group is viewed negatively because its core PBM economics are under pressure from the forced transition to the rebate-free Signature model, where earnings depend on customer acceptance of higher administrative fees while Evernorth margins have already slipped from 3.5%-4.5% to 3.0%-3.5% by CY26 Investor Day. Although specialty and Care Services are growing strongly, the company still faces concentration risk from large renewals, PBM client losses, and the exit from the Exchange business at the end of 2026, which may leave stranded overhead and dilute 2027 profitability. The outlook is also constrained by execution risk in medical cost management, network contracting, and regulatory changes, making the 10.0%-14.0% long-term EPS CAGR harder to trust without clearer evidence of durable earnings persistence.